Clinical Trial Update: Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the safety and effectiveness of Terbium-161 DOTATATE for metastatic neuroendocrine tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• Terbium-161 DOTATATE (Terbium-161 DOTATATE)

Snippet

Sponsor: Tata Memorial Hospital | Conditions: Neuroendocrine Neoplasms (Tumours), Neuroendocrine Tumors | Phase 2 | Status: RECRUITING